Cerity Partners LLC Acquires 11,399 Shares of Bristol-Myers Squibb (NYSE:BMY)

Cerity Partners LLC lifted its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 1.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 902,704 shares of the biopharmaceutical company's stock after acquiring an additional 11,399 shares during the quarter. Cerity Partners LLC's holdings in Bristol-Myers Squibb were worth $49,419,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of BMY. Norges Bank acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $1,989,525,000. Wellington Management Group LLP increased its position in Bristol-Myers Squibb by 3,880.0% during the fourth quarter. Wellington Management Group LLP now owns 5,977,505 shares of the biopharmaceutical company's stock worth $338,088,000 after buying an additional 5,827,317 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $257,618,000. Schroder Investment Management Group lifted its position in shares of Bristol-Myers Squibb by 49.7% in the fourth quarter. Schroder Investment Management Group now owns 11,413,428 shares of the biopharmaceutical company's stock valued at $639,837,000 after buying an additional 3,787,075 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Bristol-Myers Squibb by 6.4% during the 4th quarter. Bank of New York Mellon Corp now owns 24,733,868 shares of the biopharmaceutical company's stock worth $1,398,948,000 after acquiring an additional 1,482,410 shares during the period. Institutional investors own 76.41% of the company's stock.

Remove Ads

Bristol-Myers Squibb Price Performance

Shares of NYSE BMY traded up $0.22 during trading hours on Friday, hitting $50.68. 13,408,290 shares of the stock were exchanged, compared to its average volume of 12,926,949. The company's fifty day simple moving average is $57.71 and its two-hundred day simple moving average is $56.78. The company has a market cap of $103.11 billion, a PE ratio of -11.46, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. On average, sell-side analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be paid a dividend of $0.62 per share. The ex-dividend date is Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.89%. Bristol-Myers Squibb's payout ratio is presently -56.11%.

Insider Activity

In other news, EVP Samit Hirawat bought 1,823 shares of the company's stock in a transaction on Friday, February 14th. The stock was purchased at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the transaction, the executive vice president now owns 63,932 shares of the company's stock, valued at $3,506,030.88. This trade represents a 2.94 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 0.09% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Citigroup increased their price target on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. UBS Group cut their target price on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday. The Goldman Sachs Group reiterated a "neutral" rating and issued a $55.00 price target (down previously from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Jefferies Financial Group upgraded shares of Bristol-Myers Squibb from a "hold" rating to a "buy" rating and raised their price objective for the stock from $63.00 to $70.00 in a research report on Monday, December 16th. Finally, Cantor Fitzgerald upped their target price on Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of "Hold" and a consensus target price of $57.67.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.